Payment overview · 2025
General Payments
$3,520.50
166 reported records · 27 companies
Healthcare provider profile · identity verified
Hieu N Tram, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WESTMINSTER, CA · NPI 1003900366
Verified facts
What the public records show
CMS Open Payments records show Hieu N Tram, MD received $3,520.50 in general payments during 2025 across 166 reported records.
ABBVIE INC. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 751 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 751 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $495.38 | 14.1% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $443.12 | 12.6% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $438.20 | 12.4% | 20 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $211.36 | 6.0% | 11 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $192.41 | 5.5% | 10 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $190.34 | 5.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $172.38 | 4.9% | 8 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $159.42 | 4.5% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $155.14 | 4.4% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $146.49 | 4.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $129.00 | 3.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.67 | 3.5% | 6 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $93.66 | 2.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $77.29 | 2.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.21 | 2.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.98 | 2.0% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $63.82 | 1.8% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.85 | 1.2% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $42.58 | 1.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.03 | 1.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.61 | 1.0% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $27.52 | 0.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.20 | 0.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.43 | 0.6% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $19.55 | 0.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.16 | 0.5% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $15.70 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,520.50 | 166 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $443.13 | 20 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $325.74 | 20 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $241.84 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $223.02 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $221.01 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $211.36 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $201.28 | 12 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $192.41 | 10 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $190.34 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $182.08 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.41 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $159.42 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $154.19 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $146.49 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $129.00 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.67 | 6 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $93.66 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $77.29 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $77.29 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $70.98 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $70.98 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.28 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.28 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $63.82 | 3 | 2025 |
Source payment records
|
|||||
| LO LOESTRIN FE Normalized: lo loestrin fe |
Drug | ABBVIE INC. | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.85 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $42.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $27.52 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $15.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 188 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 103 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 155 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 121 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 751 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 155 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 71 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 88 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
155 | 25 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
158 | 90 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
155 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
751 | 98 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
188 | 187 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
751 | 98 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
111 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 931 | 203 |
| Vascepa | Icosapent Ethyl | 822 | 130 |
| Jardiance | Empagliflozin | 751 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 741 | 164 |
| Famotidine | Famotidine | 534 | 126 |
| Fluticasone Propionate | Fluticasone Propionate | 504 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 487 | 110 |
| Diclofenac Sodium | Diclofenac Sodium | 481 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 477 | 101 |
| Losartan Potassium | Losartan Potassium | 441 | 106 |
| Gabapentin | Gabapentin | 359 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 85 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 312 | 121 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 311 | 108 |
| Azithromycin | Azithromycin | 303 | 197 |
| Baclofen | Baclofen | 300 | 81 |
| Metformin Hcl Er | Metformin Hcl | 276 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 274 | 75 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 263 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 262 | 55 |
| Januvia | Sitagliptin Phosphate | 250 | 32 |
| Celecoxib | Celecoxib | 244 | 71 |
| Metformin Hcl | Metformin Hcl | 244 | 66 |
| Irbesartan | Irbesartan | 226 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 38 |
| Icosapent Ethyl | Icosapent Ethyl | 218 | 77 |
| Finasteride | Finasteride | 214 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 39 |
| Valsartan | Valsartan | 202 | 49 |
| Lisinopril | Lisinopril | 195 | 44 |
| Glipizide Er | Glipizide | 194 | 40 |
| Eliquis | Apixaban | 193 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 50 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 188 | 187 |
| Dexlansoprazole Dr | Dexlansoprazole | 186 | 39 |
| Alendronate Sodium | Alendronate Sodium | 183 | 40 |
| Allopurinol | Allopurinol | 177 | 40 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 165 | 73 |
| Prolia | Denosumab | 158 | 90 |
| Farxiga | Dapagliflozin Propanediol | 155 | 24 |
| Linzess | Linaclotide | 155 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 155 | 41 |
| Tradjenta | Linagliptin | 154 | 24 |
| Myrbetriq | Mirabegron | 151 | 27 |
| Dutasteride | Dutasteride | 149 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 29 |
| Omeprazole | Omeprazole | 146 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 143 | 28 |
| Cilostazol | Cilostazol | 138 | 15 |
| Azelastine Hcl | Azelastine Hcl | 129 | 35 |
| Lovastatin | Lovastatin | 126 | 29 |
| Meloxicam | Meloxicam | 125 | 60 |
| Hydrocortisone | Hydrocortisone | 124 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 123 | 88 |
| Gemtesa | Vibegron | 121 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 117 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 22 |
| Ezetimibe | Ezetimibe | 115 | 31 |
| Mounjaro | Tirzepatide | 114 | 21 |
| Trulicity | Dulaglutide | 111 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 110 | 23 |
| Silodosin | Silodosin | 110 | 25 |
| Glipizide | Glipizide | 108 | 14 |
| Montelukast Sodium | Montelukast Sodium | 106 | 26 |
| Mirtazapine | Mirtazapine | 104 | 28 |
| Creon | Lipase/Protease/Amylase | 103 | 20 |
| Sucralfate | Sucralfate | 99 | 29 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 98 | 21 |
| Nifedipine Er | Nifedipine | 95 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 91 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 21 |
| Zenpep | Lipase/Protease/Amylase | 88 | suppressed |
| Loperamide | Loperamide Hcl | 86 | 62 |
| Meclizine Hcl | Meclizine Hcl | 83 | 42 |
| Estradiol | Estradiol | 82 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 13 |
| Ketoconazole | Ketoconazole | 80 | 27 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 73 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 71 | 17 |
| Donepezil Hcl | Donepezil Hcl | 71 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 12 |
| Rybelsus | Semaglutide | 71 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | suppressed |
| Memantine Hcl | Memantine Hcl | 68 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 26 |
| Carvedilol | Carvedilol | 66 | 17 |
| Furosemide | Furosemide | 66 | 14 |
| Amoxicillin | Amoxicillin | 65 | 52 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 12 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 61 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 58 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 58 | 20 |
| Atenolol | Atenolol | 57 | 15 |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 56 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 12 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 55 | 11 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 53 | 11 |
| Prednisone | Prednisone | 53 | 32 |
| Tramadol Hcl | Tramadol Hcl | 53 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 12 |
| Nateglinide | Nateglinide | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Primidone | Primidone | 52 | suppressed |
| Ranolazine Er | Ranolazine | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 51 | 14 |
| Ciclopirox | Ciclopirox Olamine | 50 | 19 |
| Ozempic | Semaglutide | 50 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 14 |
| Topiramate | Topiramate | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 45 | suppressed |
| Procto-Med Hc | Hydrocortisone | 45 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 39 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Cefdinir | Cefdinir | 43 | 29 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Lidocaine | Lidocaine | 41 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | 20 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Ciclopirox | Ciclopirox | 35 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 33 | 33 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 25 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Colchicine | Colchicine | 32 | 12 |
| Mometasone Furoate | Mometasone Furoate | 32 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Acarbose | Acarbose | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 15 |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Cyclosporine | Cyclosporine | 30 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 17 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ursodiol | Ursodiol | 26 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 25 | suppressed |
| Calcipotriene | Calcipotriene | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Entecavir | Entecavir | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 18 |
| Ondansetron Odt | Ondansetron | 18 | 16 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Edarbi | Azilsartan Medoxomil | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Bystolic | Nebivolol Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,520.50 · 166 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, CREON, Cequa, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KISUNLA, LEQVIO, LINZESS, LO LOESTRIN FE, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Ozempic, PANCREAZE, PAXLOVID, REPATHA, REXULTI, Rybelsus, SHINGRIX, SLYND, SMARTVEST, Spinosad, Tymlos, VOQUEZNA, YUPELRI, ZENPEP, ZEPBOUND, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error